
NeurologyLive® Friday 5 — May 15, 2026
Key Takeaways
- Abbott’s R&D perspective highlights DBS evolution via improved patient phenotyping, directional leads, closed-loop or sensing-enabled systems, and streamlined programming to personalize Parkinson disease therapy.
- Advanced multimodal imaging is enabling stroke triage based on salvageable tissue rather than clock time, with telestroke networks extending expertise and accelerating reperfusion decisions.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Click the read more or watch now buttons for more details and information about each highlight.
1: How Deep Brain Stimulation is Evolving Parkinson Disease
In a recent Q&A, Rebecca Wilkins, Divisional Vice President of R&D Neuromodulation at Abbott, discusses the evolving role of deep brain stimulation in Parkinson disease, including patient selection, newer DBS technologies, and integration with emerging therapies.
2: Advancing Stroke Imaging Through Tissue-Based Decision-Making: Rahul Chandra, MD
In a recent interview, Rahul Chandra, MD, medical director for telestroke at Allegheny Health Network, discussed how evolving imaging modalities may be reshaping stroke care in honor of Stroke Awareness Month. [WATCH TIME: 5 minutes]
3: High-Dose Nusinersen and the Future of SMA Treatment
In a recent interview, Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins, discussed the FDA's recent approval of high-dose nusinersen for spinal muscular atrophy and SMA's evolving landscape of care.
4: NeuroVoices: Gus Alva, MD, DFAPA, on Potential Impact of Newly Approved AXS-05 for Alzheimer Disease Agitation
In our latest NeuroVoices Q&A, Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.
5: Highlighting Key Clinical and Research Trends From the 2026 AAN Annual Meeting
In a recent interview, H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.
Which conversation stood out most to you in this week’s NeurologyLive Friday Five?
Don’t have time to read or watch a full video interview?

















